148 related articles for article (PubMed ID: 35027056)
21. Comparison of Antibodies to Detect Uroplakin in Urothelial Carcinomas.
Kristoffersen HL; Røge R; Nielsen S
Appl Immunohistochem Mol Morphol; 2022 May-Jun 01; 30(5):326-332. PubMed ID: 35510771
[TBL] [Abstract][Full Text] [Related]
22. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference.
Amin MB; Trpkov K; Lopez-Beltran A; Grignon D;
Am J Surg Pathol; 2014 Aug; 38(8):e20-34. PubMed ID: 25029121
[TBL] [Abstract][Full Text] [Related]
23. Inverted variant of urothelial carcinoma of the urinary bladder: a report of three cases and a proposal for a new clinicopathologic entity.
Terada T
Int J Clin Exp Pathol; 2013; 6(4):766-70. PubMed ID: 23573325
[TBL] [Abstract][Full Text] [Related]
24. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.
Behzatoğlu K; Yörükoğlu K; Demir H; Bal N
Eur Urol Focus; 2018 Apr; 4(3):399-404. PubMed ID: 28753766
[TBL] [Abstract][Full Text] [Related]
25. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas.
Parker DC; Folpe AL; Bell J; Oliva E; Young RH; Cohen C; Amin MB
Am J Surg Pathol; 2003 Jan; 27(1):1-10. PubMed ID: 12502922
[TBL] [Abstract][Full Text] [Related]
26. p16 INK4a overexpression and p16/Ki-67 dual labeling versus conventional urinary cytology in the evaluation of urothelial carcinoma.
Piaton E; Carré C; Advenier AS; Decaussin-Petrucci M; Mège-Lechevallier F; Lantier P; Granier G; Ruffion A
Cancer Cytopathol; 2014 Mar; 122(3):211-20. PubMed ID: 24302621
[TBL] [Abstract][Full Text] [Related]
27. TRAIL and osteoprotegerin (OPG) expression in bladder urothelial carcinoma: correlation with clinicopathological parameters and prognosis.
Levidou G; Thymara I; Saetta AA; Papanastasiou P; Pavlopoulos P; Sakellariou S; Fragkou P; Patsouris E; Korkolopoulou P
Pathology; 2013 Feb; 45(2):138-44. PubMed ID: 23277172
[TBL] [Abstract][Full Text] [Related]
28. Small cell carcinoma of urinary bladder is differentiated from urothelial carcinoma by chromogranin expression, absence of CD44 variant 6 expression, a unique pattern of cytokeratin expression, and more intense gamma-enolase expression.
Iczkowski KA; Shanks JH; Allsbrook WC; Lopez-Beltran A; Pantazis CG; Collins TR; Wetherington RW; Bostwick DG
Histopathology; 1999 Aug; 35(2):150-6. PubMed ID: 10460660
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of CD24: association with invasiveness in urothelial carcinoma of the bladder.
Choi YL; Lee SH; Kwon GY; Park CK; Han JJ; Choi JS; Choi HY; Kim SH; Shin YK
Arch Pathol Lab Med; 2007 Feb; 131(2):275-81. PubMed ID: 17284113
[TBL] [Abstract][Full Text] [Related]
30. H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases.
Castillo-Martin M; Collazo Lorduy A; Gladoun N; Hyun G; Cordon-Cardo C
J Pediatr Urol; 2016 Apr; 12(2):91.e1-7. PubMed ID: 26522772
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical over-expression of HER2 does not always match with gene amplification in invasive bladder cancer.
Franceschini T; Capizzi E; Massari F; Schiavina R; Fiorentino M; Giunchi F
Pathol Res Pract; 2020 Aug; 216(8):153012. PubMed ID: 32703487
[TBL] [Abstract][Full Text] [Related]
32. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
33. Uroplakin as a marker for typing metastatic transitional cell carcinoma on fine-needle aspiration specimens.
Xu X; Sun TT; Gupta PK; Zhang P; Nasuti JF
Cancer; 2001 Jun; 93(3):216-21. PubMed ID: 11391610
[TBL] [Abstract][Full Text] [Related]
34. Utility of GATA-3 and associated immunohistochemical markers in the differential diagnosis of poorly differentiated urothelial carcinoma.
Naik M; Rao BV; Challa S; Fonseca D; Sudha SM; Giridhar A; Sharma R; Raju KVVN; Rao TS
J Cancer Res Ther; 2023 Apr; 19(Supplement):S0. PubMed ID: 37147963
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic and Prognostic Roles of GATA3 Immunohistochemistry in Urothelial Carcinoma.
Yoo D; Min KW; Pyo JS; Kim NY
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629741
[TBL] [Abstract][Full Text] [Related]
36. ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study.
Li HX; Li M; Li CL; Ma JH; Wang MR; Rao J; Pan QJ
Anal Quant Cytol Histol; 2010 Feb; 32(1):45-52. PubMed ID: 20701087
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques.
Nedjadi T; Al-Maghrabi J; Assidi M; Dallol A; Al-Kattabi H; Chaudhary A; Al-Sayyad A; Al-Ammari A; Abuzenadah A; Buhmeida A; Al-Qahtani M
BMC Cancer; 2016 Aug; 16():653. PubMed ID: 27539085
[TBL] [Abstract][Full Text] [Related]
38. Wnt5a / planar cell polarity signaling pathway in urothelial carcinoma, a potential prognostic biomarker.
Saling M; Duckett JK; Ackers I; Coschigano K; Jenkinson S; Malgor R
Oncotarget; 2017 May; 8(19):31655-31665. PubMed ID: 28427201
[TBL] [Abstract][Full Text] [Related]
39. [Expression and clinical significance of 5hmC in bladder urothelial carcinoma].
Li J; Xu Y; Zhang Z; Zhang M; Zhang Z; Zhang F; Li Q
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Feb; 32(2):232-5. PubMed ID: 26927384
[TBL] [Abstract][Full Text] [Related]
40. Different immunohistochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer.
Gaisa NT; Braunschweig T; Reimer N; Bornemann J; Eltze E; Siegert S; Toma M; Villa L; Hartmann A; Knuechel R
Virchows Arch; 2011 Mar; 458(3):301-12. PubMed ID: 21136076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
